第三高價股愛美客(300896.SZ)再創上市新高 逼近千億市值
格隆匯1月22日丨醫美龍頭愛美客(300896.SZ)盤中拉昇,一度漲7.46%至825元,再創上市新高,市值990億元。愛美客為A股市場第三高價股(僅次於茅台和石頭科技)。該股於去年9月底以118.27元上市,現價較IPO價格已累漲近600%。公司是國內生物醫用軟組織修復材料領域的創新型領先企業。公司致力於重組蛋白和多肽等生物醫藥的開發,已成功實現注射類透明質酸鈉系列產品及聚對二氧環己酮面部埋植線的產業化,並建立了醫用幾丁糖、聚乳酸等生物醫用材料的產品技術轉化平台,產品臨牀應用涵蓋醫療美容、外科修復以及代謝疾病治療等領域。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.